Real-world evidence to support health technology assessment and payer decision making: is it now or never?
Open Access
- 31 March 2025
- journal article
- policy
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 41 (1) , e20
Abstract
Objectives: The aim of this policy article is twofold: (i) to provide a summary and update of recent important policy developments, in particular relevant guidance on the use of real-world data/real-world evidence (RWD/RWE) by health technology assessment (HTA) bodies and (ii) to set out our policy recommendations on how the different elements of an “RWE framework” we have previously developed could support, further enhance and facilitate the use of RWE for HTA purposes and by HTA bodies and payers. Methods: We undertook a targeted review and analysis of recent important policy developments. The aim was to build on our recommendations from previous work on the “RWE Framework,” and consider how the relevant tools from our Framework can further enhance and facilitate the use of RWE for HTA purposes and by HTA bodies/payers. Results: We provide eight conditions that we argue would, in combination, constitute the optimal use and acceptance of RWD/RWE for HTA. We believe that, should the eight conditions hold, RWD/RWE would enable more efficient access to medicines and healthcare technologies for patients. Conclusions: High-quality, fit-for-purpose RWD/RWE can and should be used more frequently in HTA. Multi-stakeholder and cross-geography collaborative partnerships are needed to align on best practices to optimize the evidence that needs to be generated to satisfy all stakeholders’ needs.Keywords
Funding Information
- Novartis
This publication has 11 references indexed in Scilit:
- Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision MakingValue in Health, 2023
- Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country StudyValue in Health, 2023
- Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision MakersValue in Health, 2023
- Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way ForwardValue in Health, 2023
- The Real-World Evidence Workstream in EUreccA 2025: How the Task Was AddressedValue in Health, 2023
- Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?International Journal of Technology Assessment in Health Care, 2022
- Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?Clinical Pharmacology & Therapeutics, 2021
- Use of real-world evidence in economic assessments of pharmaceuticals in the United StatesJournal of Managed Care & Specialty Pharmacy, 2021
- Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA AgenciesPharmacoEconomics, 2017
- Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA AgenciesValue in Health, 2017